Compare Becton Dickinson and Co (BDX) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Linde PLC — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Linde PLC trades at $521.43 (market cap $241.59B). The key difference: Linde PLC is far larger — about 5.8× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | LIN | |
|---|---|---|
Market Cap | $41.51B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $546.64 |
52-Week Low | $135.49 | $389.38 |
Enterprise Value | $57.97B | $263.95B |
Dividend Yield | 2.79% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Linde (LIN) trades at $522.54, down 1.37% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $560. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a net income margin of 20.44%. Recent news highlights sustainability leadership and strategic growth, though valuation ratios like a P/E of 34.75 suggest premium pricing.
The stock offers steady growth potential driven by earnings beats and dividend consistency, but faces risks from rising debt levels and macroeconomic pressures. Analyst sentiment is overwhelmingly bullish with 85.7% buy ratings, indicating confidence in Linde's operational strength and future performance, though investors should monitor debt trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
